<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00427765</url>
  </required_header>
  <id_info>
    <org_study_id>2004-0190</org_study_id>
    <nct_id>NCT00427765</nct_id>
  </id_info>
  <brief_title>Busulfan Plus Melphalan Conditioning Regimen for Lymphoid Malignancies or Multiple Myeloma</brief_title>
  <official_title>A Phase II Study of High-Dose Intravenous Busulfan Plus Melphalan With Allogeneic or Autologous Marrow or Peripheral Blood Progenitor Cell Transplantation for Lymphoid Malignancies or Multiple Myeloma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>M.D. Anderson Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>M.D. Anderson Cancer Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Primary Objectives:

        1. To determine the efficacy of administering multiple doses of intravenous (i.v.) busulfan
           at a dose of 130 mg/m2, to yield a systemic plasma drug exposure represented by a daily
           area under the plasma concentration versus time curve (AUC) of approximately 5,000
           mMol-min for 4 days, followed by i.v. melphalan at a dose of 70 mg/m2 for 2 days in
           adult patients receiving autologous or allogeneic transplantation for lymphoid
           malignancies or myeloma.

        2. To describe the plasma pharmacokinetic (PK) profiles of busulfan and melphalan in this
           regimen.

        3. To determine the disease-free and overall survival of patients receiving this
           preparative regimen.

        4. To determine the treatment-related morbidity and mortality of this combination of drugs.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Busulfan and melphalan are both traditional alkylating agents that are designed to interfere
      with the production of cancer cells at the DNA (deoxyribonucleic acid) and RNA (ribonucleic
      acid) level.

      Before you can start treatment on this study, you will have what are called &quot;screening
      tests&quot;. These tests will help the doctor decide if you are eligible to take part in the
      study. You will have a complete physical exam, including routine blood (2-3 teaspoons) and
      urine tests. Patients will have a chest x-ray, heart scan, lung function test, and a bone
      marrow biopsy. Women who are able to have children must have a negative blood pregnancy test.

      If you are found to be eligible to take part in this study, you will be able to start
      receiving chemotherapy treatment with busulfan and melphalan. Participants who agree to the
      optional blood draws described above will at first receive a therapeutic &quot;trial dose&quot; of
      busulfan by vein to test the blood levels over time. This therapeutic trial dose of busulfan
      is about 25% (1 fourth) of the full therapeutic dose of the drug. This information will be
      used to decide what the future high-dose busulfan treatments you receive will be. If you do
      not agree to the optional blood draw, you will receive a fixed amount of high-dose busulfan
      from the start.

      On the 1st day of hospitalization, you will receive fluids by vein through a central venous
      catheter. If you choose the optional busulfan dose for pharmacokinetic-based busulfan dosing,
      you will receive the optional busulfan dose 9 days before stem cell infusion (Day 1),
      followed by a rest day on Day 2. If you choose to receive a fixed dose of busulfan, busulfan
      will be injected through a central venous catheter over 3 hours, once a day, for the next 4
      days (Days 3-6, ending 3 days before the stem cell infusion day).

      Patients receiving pharmacokinetic-based dosing of busulfan will also continue to receive
      busulfan on Days 3-6. This will be followed by melphalan for all patients, given through your
      central venous catheter over 30 minutes, once a day, for 2 days, on days 8 and 9. Your stem
      cell infusion day will be on Day 10 of treatment.

      Patients receiving 5 out of 6 antigen matched-related allogeneic stem cell transplants or
      unrelated allogeneic stem cell transplants will also receive antithymocyte globulin (ATG), by
      vein, on Days 7-9, up to one day before the stem cell infusion. This is given to decrease the
      risk of GVHD and graft rejection in mismatched transplants.

      On Day 10, healthy blood stem cells or bone marrow from the donor will be given through the
      central catheter. This is your transplant date. You will also receive several other
      medications to help the treatment work and to help prevent infections while your immune
      system is weak. Tacrolimus and methotrexate will be given to decrease the risk of
      graft-versus-host-disease (GVHD). GVHD occurs when the donor's immune cells fight the
      patient's body. The tacrolimus will be started on the day before the transplant and will
      continue for up to six months. Tacrolimus is given by vein at first and then by mouth when
      you are able to eat. Methotrexate is given by vein on Days 11, 13, 16, and possibly on Day
      21, up to 11 days after the transplant.

      Please note that the treatment dates listed above were used to help explain your general
      treatment plan. By standard medical convention, the day of stem cell infusion is always
      listed as day zero. Therefore, the days listed above are different from the treatment plan
      described in the protocol and abstract.

      Sulfamethoxazole (Bactrim) or pentamidine will be given to fight bacteria. Bactrim is given
      by mouth when the counts are good. Pentamidine is given by vein when the counts are low.
      Acyclovir will be given at first by vein and then Valtrex (valacyclovir) will be given by
      pill to decrease the risk of viral infections. Granulocyte colony-stimulating factor (G-CSF)
      will be given to help the new bone marrow grow. It is given as an injection under the skin
      after the transplant. It will continue until the white blood cells reach an acceptable level.
      Overall, some of these drugs will be given for as long as 6 months or possibly longer. Other
      medications may be necessary. If you are allergic to some of these drugs, changes will be
      made.

      You will be in the hospital for about 3-4 weeks. You will have checkups every day until
      discharged from the hospital. You will then be seen in the outpatient clinic at least 3 times
      a week until your blood counts improve. You will be seen by your doctor at least every week
      until 100 days after the bone marrow transplant. You must stay in Houston during this time.
      After 100 days, you will return to the clinic according to your individual physician's
      recommendations.

      Some patients may need to receive spinal taps with instillation of chemotherapy several times
      over the year after transplantation. This is only for patients with a previous clinical
      history of leukemic involvement of the brain or high risk of developing leukemia relapse in
      the brain. The spinal tap is performed in the clinic. You are given local anesthetic at the
      lower back site, a small needle is inserted in the space between 2 spinal bones, a small
      amount of fluid that bathes the brain (cerebrospinal fluid) is removed for testing, and a
      small amount of chemotherapy is given.

      Bone marrow samples will be taken at about 1 month and 3 months after the transplant. You
      will also have a lung function test at 3 months after the transplant.

      This is an investigational study. The FDA has approved all of the drugs used in this study
      for use in stem cell transplantation. Up to 168 patients will take part in this study. All
      will be enrolled at M. D. Anderson.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2004</start_date>
  <completion_date type="Actual">November 2010</completion_date>
  <primary_completion_date type="Actual">November 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Average Overall Survival Time</measure>
    <time_frame>Baseline(transplantation) to disease progression or death for any reason, up to 6 years.</time_frame>
    <description>Average number of years for survival post transplant where overall survival time is measured from date of transplant to disease progression or death for any reason.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">168</enrollment>
  <condition>Multiple Myeloma</condition>
  <condition>Lymphoma</condition>
  <arm_group>
    <arm_group_label>Busulfan + Melphalan</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Busulfan 32 mg/m^2 intravenous (IV) for 1 Day then 130 mg/m^2 IV for 4 Days; and Melphalan 70 mg/m^2 IV for 2 Days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Busulfan</intervention_name>
    <description>Test Dose = 32 mg/m^2 IV for 1 Day; 130 mg/m^2 IV for 4 Days</description>
    <arm_group_label>Busulfan + Melphalan</arm_group_label>
    <other_name>Busulfex</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Melphalan</intervention_name>
    <description>70 mg/m^2 IV for 2 Days</description>
    <arm_group_label>Busulfan + Melphalan</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with lymphoid malignancies, including Hodgkin's and non-Hodgkin's lymphoma
             (primary refractory or recurrent), or multiple myeloma (beyond first complete
             remission or unresponsive to therapy. Complete remission for multiple myeloma defined
             by absence of detectable paraprotein in serum and/or urine by immunoelectrophoresis or
             immunofixation, and &lt; 5% plasma cells in the bone marrow), not qualifying for
             treatment protocols of higher priority.

          -  Age 18 to 65 years of age.

          -  Adequate renal function as defined by estimated serum creatinine clearance &gt; 50 ml/min
             and serum creatinine &lt; 1.8 mg/dL.

          -  Adequate hepatic function, as defined by serum glutamic pyruvic transaminase (SGPT) &lt;
             3 * upper limit of normal; serum bilirubin and alkaline phosphatase &lt; 2 * upper limit
             of normal, or considered not clinically significant.

          -  Adequate pulmonary function with Forced expiratory volume in one second (FEV1), forced
             vital capacity (FVC), and Capacity of the Lung for Carbon Monoxide (DLCO)&gt; 50%.
             Exceptions may be allowed for patients with pulmonary involvement after discussing
             with principal investigator (PI).

          -  Adequate cardiac function with left ventricular ejection fraction &gt;/= 40%. No
             uncontrolled arrhythmias or symptomatic cardiac disease.

          -  Zubrod performance score &lt; 2.

          -  Patients receiving an allogeneic transplant must have an HLA matched, or one A, B, or
             DR mismatched related donor. Unrelated donor must be matched at A, B, and DR (defined
             as A, B serologic matched and DRB1 molecular matched). Donor must be willing to donate
             peripheral blood or bone marrow progenitor cells.

          -  Patient and donor should be willing to participate in the study by providing written
             consent.

          -  Female patient must not be pregnant and have negative pregnancy.

        Exclusion Criteria:

          -  Patients with unresolved grade &gt;/= 3 non-hematologic toxicity from previous therapy.
             Patients with grade 2 toxicity will be eligible at the discretion of the PI.

          -  Patients with active Central Nervous System (CNS) disease.

          -  Evidence of acute or chronic active hepatitis or cirrhosis. If positive hepatitis
             serology, discuss with Study Chairman and consider liver biopsy.

          -  Uncontrolled infection, including Human immunodeficiency virus (HIV) or Human
             T-lymphotropic virus Type I (HTLV-1) infection.

          -  Patients who have had a previous autologous or allogeneic stem cell transplant during
             the past year.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Partow Kebriaei, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>M.D. Anderson Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UT MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mdanderson.org</url>
    <description>UT MD Anderson Cancer Center</description>
  </link>
  <verification_date>December 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 25, 2007</study_first_submitted>
  <study_first_submitted_qc>January 25, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 29, 2007</study_first_posted>
  <results_first_submitted>November 14, 2011</results_first_submitted>
  <results_first_submitted_qc>December 15, 2011</results_first_submitted_qc>
  <results_first_posted type="Estimate">January 19, 2012</results_first_posted>
  <last_update_submitted>December 15, 2011</last_update_submitted>
  <last_update_submitted_qc>December 15, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 19, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Multiple Myeloma</keyword>
  <keyword>Hodgkin's Disease</keyword>
  <keyword>Non-Hodgkin's Lymphoma</keyword>
  <keyword>Leukemia</keyword>
  <keyword>Lymphoma</keyword>
  <keyword>Busulfan</keyword>
  <keyword>Melphalan</keyword>
  <keyword>Autologous bone marrow</keyword>
  <keyword>BMT</keyword>
  <keyword>Peripheral blood stem cell transplant</keyword>
  <keyword>PBSCT</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melphalan</mesh_term>
    <mesh_term>Busulfan</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Recruitment Period: 2/4/2005 through 10/29/2010. All participant recruitment attempted at UT MD Anderson Cancer Center.</recruitment_details>
      <pre_assignment_details>Among the participants enrolled, two were excluded from the trial before starting any treatment. There are two participants who were enrolled on the study twice (having to temporarily leave then re-enter the study).</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Busulfan + Melphalan</title>
          <description>Busulfan 32 mg/m^2 intravenous (IV) for 1 Day then 130 mg/m^2 IV for 4 Days; and Melphalan 70 mg/m^2 IV for 2 Days</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="164"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="164"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Busulfan + Melphalan</title>
          <description>Busulfan 32 mg/m^2 intravenous (IV) for 1 Day then 130 mg/m^2 IV for 4 Days; and Melphalan 70 mg/m^2 IV for 2 Days</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="164"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="42" lower_limit="18" upper_limit="66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="164"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Average Overall Survival Time</title>
        <description>Average number of years for survival post transplant where overall survival time is measured from date of transplant to disease progression or death for any reason.</description>
        <time_frame>Baseline(transplantation) to disease progression or death for any reason, up to 6 years.</time_frame>
        <population>Analysis by protocol</population>
        <group_list>
          <group group_id="O1">
            <title>Busulfan + Melphalan</title>
            <description>Busulfan 32 mg/m^2 intravenous (IV) for 1 Day then 130 mg/m^2 IV for 4 Days; and Melphalan 70 mg/m^2 IV for 2 Days</description>
          </group>
        </group_list>
        <measure>
          <title>Average Overall Survival Time</title>
          <description>Average number of years for survival post transplant where overall survival time is measured from date of transplant to disease progression or death for any reason.</description>
          <population>Analysis by protocol</population>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="164"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3" lower_limit="0.1" upper_limit="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>5 years and 9 months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Busulfan + Melphalan</title>
          <description>Busulfan 32 mg/m^2 intravenous (IV) for 1 Day then 130 mg/m^2 IV for 4 Days; and Melphalan 70 mg/m^2 IV for 2 Days</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTCAE (3.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="31" subjects_at_risk="164"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Esophagitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="164"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>Graft Vs Host Disease</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>Ascites</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>Graft Failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>Portal Vein Flow</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="164"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperbilirubinemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>Veno-Occlusive Disease</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="164"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infection/Sepsis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="164"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Acute Renal Failure</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="164"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diffuse Alveolar Hemorrhage</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>Pleural Effusion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>Respiratory Failure</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="164"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>CTCAE (3.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="164" subjects_at_risk="164"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Thrombotic Thrombocytopenic purpura</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="164"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Dysrhythmia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>Edema</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="164"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="110" subjects_affected="110" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>Mucositis</sub_title>
                <counts group_id="E1" events="138" subjects_affected="138" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="156" subjects_affected="156" subjects_at_risk="164"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fever</sub_title>
                <counts group_id="E1" events="16" subjects_affected="16" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>Neutropenic Fever</sub_title>
                <counts group_id="E1" events="72" subjects_affected="72" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>Confusion</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>Graft Vs Host Disease</sub_title>
                <counts group_id="E1" events="48" subjects_affected="48" subjects_at_risk="164"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Elevated Alkaline Phosphatase</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>Elevated Alanine Aminotransferase</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>Elevated Bilirubin</sub_title>
                <counts group_id="E1" events="11" subjects_affected="11" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>Veno-Occlusive Disease</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="164"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infections</sub_title>
                <counts group_id="E1" events="70" subjects_affected="70" subjects_at_risk="164"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Guillain-Barre Syndrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>Cranial Nerve Palsy</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>Seizure</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>Neuropathy</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="164"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Elevated Creatinine</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>Hemorrhagic Cystitis</sub_title>
                <counts group_id="E1" events="16" subjects_affected="16" subjects_at_risk="164"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pulmonary Hemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="12" subjects_affected="12" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>Shortness of Breath</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="164"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" events="13" subjects_affected="13" subjects_at_risk="164"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Partow Kebriaei, MD/Associate Professor</name_or_title>
      <organization>UT MD Anderson Cancer Center</organization>
      <email>celsaenz@mdanderson.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

